The Outcome of Six-month Clinical Trial with Eucatax Paclitaxel Eluting Stent Compared With Eucastsflex Bare Metal Stent in Patients Undergoing De Novo Coronary Stenting

AUTHORS

Mohammad Ali Ostovan 1 , M Rezaie 1 , * , Javad Kojuri 1

1 Cardiovascular Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

How to Cite: Ostovan M A, Rezaie M , Kojuri J . The Outcome of Six-month Clinical Trial with Eucatax Paclitaxel Eluting Stent Compared With Eucastsflex Bare Metal Stent in Patients Undergoing De Novo Coronary Stenting, Int Cardio Res J. 2010 ; 4(2):e65013.

ARTICLE INFORMATION

International Cardiovascular Research Journal: 4 (2); e65013
Published Online: June 30, 2010
Article Type: Research Article
Received: December 17, 2017
Accepted: June 30, 2010
READ FULL TEXT

Abstract

Background: Superiority of paclitaxel-eluting stents over bare metal stents in angiographic and clinical outcomes
have been shown in many trials . Eucatax stents is a newly developed paclitaxel eluting stent using biodegradable
polymer matrix. To our knowledge there have been no studies directly comparing Eucatax paclitaxel
eluting stents with EucaSTSflex bare metal stents. The aim of this study is to evaluate short-term benefits of
Eucatax in comparison with EucaSTSflex in patients undergoing denovo coronary stenting.
Methods: A retrospective comparison of Eucatax versus EucaSTSflex was conducted among 89 consecutive
patients (44 Eucatax, 45 EucaSTSflex) in Kowsar heart institute, with at least one successfully deployed stent in
de novo lesions over a 6-month period. Outcomes included death ,nonfatal MI, CABG, late stent thrombosis
at six month, as well as functional evidence of ischemia evaluated by exercise treadmill test(ETT) or cardiac
scan( SPECT).
Results: From April to July 2008, a total of 89 patients (44 Eucatax, 45 EucaSTSflex) were evaluated after PCI
for de novo coronary lesions.
After six month follow up no difference was observed in term of death ,MI,CABG and late stent thrombosis
between Eucatax compared with EucaSTSflex. Also a non-statistically significant lower rate of positive ETT (or
SPECT) was found in Eucatax group after six month.
Conclusion: Paclitaxel eluting stents(Eucatax)are not superior to bare metal stents(EucaSTSflex) in regard to
short-term clinical outcome.

Fulltext

The full text is available in PDF.

References

  • 1.

    The references are available in PDF.

  • © 2010, Shiraz University of Medical Sciences.
    COMMENTS

    LEAVE A COMMENT HERE: